TY - THES A1 - Reyna González, Emmanuel T1 - Engineering of the microviridin post-translational modification enzymes for the production of synthetic protease inhibitors T1 - Manipulation der posttranslationalen Modifikationsenzyme von Microviridin zur Herstellung synthetischer Proteaseinhibitoren N2 - Natural products and their derivatives have always been a source of drug leads. In particular, bacterial compounds have played an important role in drug development, for example in the field of antibiotics. A decrease in the discovery of novel leads from natural sources and the hope of finding new leads through the generation of large libraries of drug-like compounds by combinatorial chemistry aimed at specific molecular targets drove the pharmaceutical companies away from research on natural products. However, recent technological advances in genetics, bioinformatics and analytical chemistry have revived the interest in natural products. The ribosomally synthesized and post-translationally modified peptides (RiPPs) are a group of natural products generated by the action of post-translationally modifying enzymes on precursor peptides translated from mRNA by ribosomes. The great substrate promiscuity exhibited by many of the enzymes from RiPP biosynthetic pathways have led to the generation of hundreds of novel synthetic and semisynthetic variants, including variants carrying non-canonical amino acids (ncAAs). The microviridins are a family of RiPPs characterized by their atypical tricyclic structure composed of lactone and lactam rings, and their activity as serine protease inhibitors. The generalities of their biosynthetic pathway have already been described, however, the lack of information on details such as the protease responsible for cleaving off the leader peptide from the cyclic core peptide has impeded the fast and cheap production of novel microviridin variants. In the present work, knowledge on leader peptide activation of enzymes from other RiPP families has been extrapolated to the microviridin family, making it possible to bypass the need of a leader peptide. This feature allowed for the exploitation of the microviridin biosynthetic machinery for the production of novel variants through the establishment of an efficient one-pot in vitro platform. The relevance of this chemoenzymatic approach has been exemplified by the synthesis of novel potent serine protease inhibitors from both rationally-designed peptide libraries and bioinformatically predicted microviridins. Additionally, new structure-activity relationships (SARs) could be inferred by screening microviridin intermediates. The significance of this technique was further demonstrated by the simple incorporation of ncAAs into the microviridin scaffold. N2 - Naturstoffe und ihre Derivate waren schon immer eine Quelle von Leitstrukturen. Insbesondere haben bakterielle Verbindungen eine wichtige Rolle bei der Arzneimittelentwicklung gespielt, zum Beispiel im Bereich der Antibiotika. Die Abnahme von Entdeckungen neuer Leitstrukturen aus natürlichen Quellen und die Hoffnung, neue Leitstrukturen in großen Bibliotheken medikamentenähnlicher Verbindungen zu finden, welche auf spezifische molekulare Ziele gerichtet sind und mithilfe kombinatorischer Chemie erstellt wurden, trieben die Pharmaunternehmen weg von der Naturstoffforschung. Allerdings haben moderne technologische Fortschritte in der Genetik, der Bioinformatik und der analytischen Chemie das Interesse an Naturstoffen wiederbelebt. Die ribosomal synthetisierten und posttranslational modifizierten Peptide (RiPPs) sind eine Gruppe von Naturstoffen, die durch das Einwirken posttranslational modifizierender Enzymen auf Präkursorpeptide entstehen, welche ihrerseits aus mRNA durch Translation an den Ribosomen hervorgehen. Die durch viele der Enzyme aus RiPP Biosynthesewege gezeigte große Substrat- Promiskuität führte zur Erzeugung hunderter neuartiger synthetischer und halbsynthetischer Varianten, einschließlich Varianten mit nicht-kanonischen Aminosäuren. Die Microviridine sind eine Familie von RiPPs, die durch ihre atypische trizyklische Struktur aus Lacton- und Lactamringen und ihre Aktivität als Serin-Protease-Inhibitoren gekennzeichnet sind. Die Grundlagen ihres Biosyntheseweges sind bereits beschrieben worden, aber wesentliche Fragestellungen, zum Beispiel die für die Spaltung des Leader-Peptids vom zyklischen Core- Peptid verantwortliche Protease betreffend, sind weitgehend ungeklärt und erschweren die schnelle und kostengünstige Herstellung neuer Microviridinvarianten. In der vorliegenden Arbeit wurde das Wissen über die durch Leader-Peptid Aktivierung von Enzymen aus anderen RiPP-Familien auf die Microviridinfamilie extrapoliert, wodurch es möglich wurde, die Notwendigkeit eines Leader-Peptids zu umgehen. Diese Besonderheit erlaubt nunmehr, die Microviridin-Biosynthese-Enzyme für die Herstellung von neuartigen Varianten durch die Etablierung einer effizienten in vitro Synthese-Plattform auszunutzen. Die Relevanz dieses chemoenzymatischen Ansatzes wurde durch die Synthese von neuen potenten Serin-Protease- Inhibitoren aus sowohl rational gestalteten Peptidbibliotheken als auch bioinformatisch vorhergesagten Microviridinen veranschaulicht. Darüber hinaus wurden durch das Screenen von Microviridinzwischenprodukten neue Struktur-Funktionsbeziehungen abgeleitet. Die Bedeutung dieser Technik wurde durch den einfachen Einbau von nicht-kanonischen Aminosäuren in das Microviridin-Gerüst weiter demonstriert. KW - RiPP KW - microviridin KW - biosynthesis KW - natural products KW - peptide KW - protease inhibitor KW - Biosynthese KW - Naturstoffe KW - cyanobacteria KW - Cyanobakterien KW - Microviridin KW - Protease-Inhibitoren Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-406979 ER - TY - JOUR A1 - Reyna-González, Emmanuel A1 - Schmid, Bianca A1 - Petras, Daniel A1 - Süssmuth, Roderich D. A1 - Dittmann, Elke T1 - Leader Peptide-Free In Vitro Reconstitution of Microviridin Biosynthesis Enables Design of Synthetic Protease-Targeted Libraries JF - Angewandte Chemie : a journal of the Gesellschaft Deutscher Chemiker ; International edition N2 - Microviridins are a family of ribosomally synthesized and post-translationally modified peptides with a highly unusual architecture featuring non-canonical lactone as well as lactam rings. Individual variants specifically inhibit different types of serine proteases. Here we have established an efficient in vitro reconstitution approach based on two ATP-grasp ligases that were constitutively activated using covalently attached leader peptides and a GNAT-type N-acetyltransferase. The method facilitates the efficient in vitro one-pot transformation of microviridin core peptides to mature microviridins. The engineering potential of the chemo-enzymatic technology was demonstrated for two synthetic peptide libraries that were used to screen and optimize microviridin variants targeting the serine proteases trypsin and subtilisin. Successive analysis of intermediates revealed distinct structure-activity relationships for respective target proteases. KW - biosynthesis KW - cyanobacteria KW - microviridins KW - natural products KW - peptides Y1 - 2016 U6 - https://doi.org/10.1002/anie.201604345 SN - 1433-7851 SN - 1521-3773 VL - 55 SP - 9398 EP - 9401 PB - Wiley-VCH CY - Weinheim ER - TY - JOUR A1 - Ahmed, Muhammad N. A1 - Reyna-Gonzalez, Emmanuel A1 - Schmid, Bianca A1 - Wiebach, Vincent A1 - Suessmuth, Roderich D. A1 - Dittmann, Elke A1 - Fewer, David P. T1 - Phylogenomic Analysis of the Microviridin Biosynthetic Pathway Coupled with Targeted Chemo-Enzymatic Synthesis Yields Potent Protease Inhibitors JF - ACS chemical biology N2 - Natural products and their semisynthetic derivatives are an important source of drugs for the pharmaceutical industry. Bacteria are prolific producers of natural products and encode a vast diversity of natural product biosynthetic gene clusters. However, much of this diversity is inaccessible to natural product discovery. Here, we use a combination of phylogenomic analysis of the microviridin biosynthetic pathway and chemo-enzymatic synthesis of bioinformatically predicted microviridins to yield new protease inhibitors. Phylogenomic analysis demonstrated that microviridin biosynthetic gene clusters occur across the bacterial domain and encode three distinct subtypes of precursor peptides. Our analysis shed light on the evolution of microviridin biosynthesis and enabled prioritization of their chemo-enzymatic production. Targeted one-pot synthesis of four microviridins encoded by the cyanobacterium Cyanothece sp. PCC 7822 identified a set of novel and potent serine protease inhibitors, the most active of which had an IC50 value of 21.5 nM. This study advances the genome mining techniques available for natural product discovery and obviates the need to culture bacteria. Y1 - 2017 U6 - https://doi.org/10.1021/acschembio.7b00124 SN - 1554-8929 SN - 1554-8937 VL - 12 SP - 1538 EP - 1546 PB - American Chemical Society CY - Washington ER -